NCT05016934 is a Phase 1, PHASE2 clinical trial of A vaccine composed of a recombinant S1 antigen in Covid19, sponsored by Hospital do Coracao.

Who is sponsoring NCT05016934?

NCT05016934 is sponsored by Hospital do Coracao.

What drugs are being tested in NCT05016934?

Interventions in NCT05016934: A vaccine composed of a recombinant S1 antigen.

Is NCT05016934 still recruiting?

NCT05016934 is currently withdrawn. Last updated 27 August 2021.

Last reviewed 2021-08-27 · How we verify

NCT05016934

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized

Withdrawn Phase 1, PHASE2 Last updated 27 August 2021

What this trial tests

Phase 1, PHASE2 trial testing A vaccine composed of a recombinant S1 antigen in Covid19. Withdrawn.

Timeline

1 November 2021

Primary endpoint
4 March 2022

20 April 2022

Quick facts

Lead sponsor	Hospital do Coracao
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Start date	1 November 2021
Primary completion	4 March 2022
Estimated completion	20 April 2022

Drugs / interventions tested

A vaccine composed of a recombinant S1 antigen — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Hospital do Coracao

Who can join

Adults 18 to 90, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized controlled trial to evaluate safety, immunogenicity and efficacy of three different doses (10, 25 and 50 mcg) of a novel vaccine compared with placebo in adult volunteers previously immunized against Covid-19 with other vaccines \[Corona Vac (Sinovac), ChAdOx1 (AZ 1222, Astra Zeneca) or Ad26.Co2.S (Janssen)\].

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Efficacy and safety of COVID-19 vaccines.
Graña C, Ghosn L, Evrenoglou T, Jarde A, et al · · 2022 · cited 227× · PMID 36473651 · DOI 10.1002/14651858.cd015477
A Narrative Review of COVID-19 Vaccines.
Eroglu B, Nuwarda RF, Ramzan I, Kayser V. · · 2021 · cited 38× · PMID 35062723 · DOI 10.3390/vaccines10010062

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Hospital do Coracao trials

Trials by the same sponsor.

NCT07534163 — III Brazilian Registry of Heart Failure · not yet recruiting
NCT07129733 — Oral Care Layered Enhancement for Improved Oral Hygiene in Intensive Care Units · NA · not yet recruiting
NCT07037524 — Low Dose Radiotherapy for Heart Failure · Phase 1, PHASE2 · not yet recruiting
NCT06546137 — National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Un · recruiting
NCT06547892 — Use of Vasopressin in Patients at High Risk of Acute Kidney Injury Admitted to the ICU · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05016934 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital do Coracao
Last refreshed: 27 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05016934.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing